Radiation impact in breast cancer

Breast Cancer Research

Volumn 11, Issue SUPPL. 3, 2009, Pages

  Ragaz, Joseph ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; FLUOROURACIL; METHOTREXATE;

ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; DISEASE MARKER; HUMAN; MASTECTOMY; METASTASIS; TREATMENT OUTCOME; ADJUVANT CHEMOTHERAPY; BREAST TUMOR; FEMALE; MULTIMODALITY CANCER THERAPY; REVIEW;

BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; FEMALE; HUMANS; TREATMENT OUTCOME;

EID: 77951891063     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr2433     Document Type: Article

References (20)

1. Ragaz J, Jackson SM, Le N, Plenderleith IH, Spinelli JJ, Basco VE, Wilson KS, Knowling MA, Coppin CM, Paradis M, Coldman AJ, Olivotto IA. Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer [see comments]. N Engl J Med 1997, 337:956-962. 9309100, 10.1056/NEJM199710023371402.
2. Overgaard M, Hansen PS, Overgaard J, Rose C, Andersson M, Bach F, Kjaer M, Gadeberg CC, Mouridsen HT, Jensen MB, Zedeler K. Postoperative radiotherapy in high-risk pre-menopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial. N Engl J Med 1997, 337:949-955. 9395428, 10.1056/NEJM199710023371401.
3. Bonadonna G, Brusamolino E, Valagussa P, Rossi A, Brugnatelli L, Brambilla C, De Lena M, Tancini G, Bajetta E, Musumeci R, Veronesi U. Combination chemotherapy as an adjuvant treatment in operable breast cancer. N Engl J Med 1976, 294:405-410.
4. Fisher B, Carbone P, Economou SG, Frelick R, Glass A, Lerner H, Redmond C, Zelen M, Band P, Katrych DL, Wolmark N, Fisher ER. L-Phenylalanine mustard (L-PAM) in the management of primary breast cancer: a report of early findings. N Engl J Med 1975, 292:117-122.
5. Cuzick J. Overview of adjuvant radiotherapy for breast cancer. Recent Results Cancer Res 1988, 111:105-107.
6. Early Breast Cancer Trialists Collaborative Group Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. The Lancet 2005, 366:2087-2106. Early Breast Cancer Trialists Collaborative Group.
7. Law LW. Origin of the resistance of leukaemic cells to folic acid anatagonists. Nature 1952, 169:628-629. 14929259, 10.1038/169628a0.
8. Goldie JH, Coldman AJ. A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep 1979, 63:1727-1733.
9. Skipper HE. Implications of biochemical, cytokinetic, pharmacologic, and toxicologic relationship in the design of optimal therapeutic schedules. Cancer Chemother Rep 1970, 54:431-450.
10. Skipper HE. Tumor differences, drug differences and effects on therapeutic outcome. Prog Clin Biol Res 1990, 354A:81-99.
11. Steel G. Growth Kinetics of Tumors 1977, 57-62. Oxford: Clarendon Press.
12. Ragaz J, Olivotto IA, Spinelli JJ, Phillips N, Jackson SM, Wilson KS, Knowling MA, Coppin CM, Weir L, Gelmon K, Le N, Durand R, Coldman AJ, Manji M. Locoregional radiation therapy in patients with high-risk breast cancer receiving adjuvant chemotherapy: 20-year results of the British Columbia randomized trial. J Natl Cancer Inst 2005, 97:116-126.
13. Nielsen HM, Overgaard M, Grau C, Jensen AR, Overgaard J. Study of failure pattern among high-risk breast cancer patients with or without postmastectomy radiotherapy in addition to adjuvant systemic therapy: long-term results from the Danish Breast Cancer Cooperative Group DBCG 82 b and c randomized studies. J Clin Oncol 2006, 24:2268-2275. 16618947, 10.1200/JCO.2005.02.8738.
14. Anonymous Favourable and unfavourable effects on long-term survival of radiotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet 2000, 355:1757-1770. 10832826, 10.1016/S0140-6736(00)02263-7, Anonymous.
15. Marks LB, Zeng J, Prosnitz LR. One to three versus four or more positive nodes and postmastectomy radiotherapy: time to end the debate. J Clin Oncol 2008, 26:2075-2077. 18445836, 10.1200/JCO.2007.15.5200.
16. Cheng SH, Horng CF, West M, Huang E, Pittman J, Tsou MH, Dressman H, Chen CM, Tsai SY, Jian JJ, Liu MC, Nevins JR, Huang AT. Genomic prediction of locoregional recurrence after mastectomy in breast cancer. J Clin Oncol 2006, 24:4594-4602. 17008701, 10.1200/JCO.2005.02.5676.
17. Truong PT, Woodward WA, Thames HD, Ragaz J, Olivotto IA, Buchholz TA. The ratio of positive to excised nodes identifies high-risk subsets and reduces inter-institutional differences in locoregional recurrence risk estimates in breast cancer patients with 1-3 positive nodes: an analysis of prospective data from British Columbia and the M. D. Anderson Cancer Center. Int J Radiat Oncol Biol Phys 2007, 68:59-65.
18. Ragaz J, Worth A, Le N, Hayes M. Extracapsular spread: adverse prognostic factor in chemotherapy-treated Stage I-II breast cancer, predictive for survival impact of locoregional radiotherapy. Observation from the British Columbia Randomized Trial. Breast Cancer Res Treat 1999, A411:57-58.
19. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, Baehner FL, Walker MG, Watson D, Park T, Hiller W, Fisher ER, Wickerham DL, Bryant J, Wolmark N. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004, 351:2817-2826. 15591335, 10.1056/NEJMoa041588.
20. Arriagada R, Rutqvist LE, Mattsson A, Kramar A, Rotstein S. Adequate locoregional treatment for early breast cancer may prevent secondary dissemination [see comments]. J Clin Oncol 1995, 13:2869-2878.